What Are the Early Warning Signs of an IMNM Relapse?
At a Glance
An immune-mediated necrotizing myopathy relapse may first appear as a sustained rise in the muscle enzyme creatine kinase (CK), sometimes weeks or months before weakness. New trouble with daily activities or swallowing should prompt a call to the care team.
Monitoring for an Immune-Mediated Necrotizing Myopathy (IMNM) relapse involves two complementary and equally important tracks: your routine bloodwork and your day-to-day physical function.
For many patients, routine bloodwork provides the most reliable early warning system. A sustained, rapid rise in Creatine Kinase (CK)—an enzyme released when muscle tissue is damaged—frequently precedes obvious physical muscle weakness by weeks or even months [1][2]. Because this “biochemical relapse” often happens silently before a clinical one (when you actually feel weak), strict adherence to your regular monitoring schedule is one of the best ways to catch disease activity early.
However, lab results do not replace paying attention to your body. You should never ignore new or worsening weakness, fatigue, or swallowing difficulties just because your recent labs were normal.
Track 1: The Biochemical Warning Signs (Bloodwork)
Your care team tracks several markers in your blood to monitor IMNM activity. An upward trend in these numbers is a common early indicator that a relapse may be starting, especially if your immunosuppressive medications are currently being tapered [3][1].
When reviewing your bloodwork, your doctors are looking for a trend compared to your personal recovery baseline, not just a single abnormal number. A solitary elevated result on your patient portal does not automatically mean a relapse—CK can rise temporarily from strenuous exercise, a fall, an injection, or a minor infection.
- Creatine Kinase (CK): A sharp, sustained increase from your baseline is a primary red flag [1]. Keep in mind that many patients who recover their muscle strength continue to have mildly elevated CK levels [4]; your doctor will focus on a steady, worsening trend.
- Aldolase: This is another muscle enzyme. While not required for every patient, some doctors check it selectively. In certain situations, particularly in anti-SRP IMNM, a rise in aldolase has been observed before obvious clinical symptoms appear [5].
- AST and ALT: Although commonly known as liver enzymes, AST and ALT are also found in muscle. Elevated levels can sometimes act as an early sign of IMNM muscle injury [6]. Because they are nonspecific, your doctor will interpret them alongside CK and other liver tests to confirm the cause rather than assuming it is a liver problem.
- Autoantibody Levels: For some subtypes, like anti-HMGCR, changes in autoantibody levels may correlate with disease activity [7]. However, these tests are not generally used alone to guide medication changes.
Track 2: Subtle Physical Clues
Because blood tests are only a snapshot in time, tracking your daily function is essential. You may notice subtle physical changes before you experience profound weakness.
- Mild Functional Changes: Pay attention to small shifts in your daily effort. You might find yourself using your arms to push up from a chair more often, or noticing a subtle increase in effort when climbing stairs, lifting objects, or raising your arms to wash your hair [8].
- Swallowing Difficulties (Dysphagia): Trouble swallowing can be a direct manifestation of IMNM disease activity [9]. Watch for new coughing when drinking liquids, a wet or gurgly voice after swallowing, or feeling like food is getting stuck.
What To Do If You Notice a Change
Relapse concerns can be stressful, but having a clear plan helps you stay in control of your care safely.
- Keep scheduled monitoring: Because a biochemical relapse occurs silently inside your body, skipping routine lab appointments removes your early warning system.
- Do not change your medications: Never stop, restart, or adjust your immunosuppressive medication doses on your own, even if your labs rise. Your doctor must assess your full clinical picture to decide if a taper should be paused or adjusted.
- Contact your care team promptly: If you notice a sustained rise in your portal lab results, new functional weakness (like trouble standing), or mild swallowing issues (like coughing with liquids), reach out to your clinic within a day or two.
- Seek urgent/emergency care: Do not wait for a scheduled appointment or blood test if you experience severe symptoms. Call emergency services or go to the nearest emergency room if you cannot swallow saliva or fluids, are actively choking, or experience shortness of breath.
Common questions in this guide
Can an IMNM relapse start with abnormal bloodwork before I feel weak?
What CK result should make me worry about an IMNM relapse?
What everyday changes can signal that IMNM is returning?
Are swallowing changes an early sign of IMNM relapse?
What should I do if my IMNM blood tests rise?
Which other blood tests may be checked for IMNM activity?
Related questions
Show more
Get notified when new evidence is published on Immune-mediated necrotizing myopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.
Ramanathan S, Langguth D, Hardy TA, et al.
Neurology(R) neuroimmunology & neuroinflammation 2015; (2(3)):e96 doi:10.1212/NXI.0000000000000096.
PMID: 25866831 - 2
Cohort study of 23 patients with seropositive immune-mediated necrotizing myopathy.
Batton R, Roullée L, Carrette M, et al.
La Revue de medecine interne 2026; (47(8)):415-423 doi:10.1016/j.revmed.2026.07.006.
PMID: 42562677 - 3
Therapeutic management of immune-mediated necrotizing myositis.
Weeding E, Tiniakou E
Current treatment options in rheumatology 2021; (7(2)):150-160 doi:10.1007/s40674-021-00174-1.
PMID: 34422547 - 4
Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.
Pinal-Fernandez I, Parks C, Werner JL, et al.
Arthritis care & research 2017; (69(2)):263-270 doi:10.1002/acr.22920.
PMID: 27111848 - 5
Anti-SRP immune-mediated necrotizing myopathy from childhood to adulthood: A case series highlighting rituximab-responsive disease.
Ahn SJ, Kim JM, Lee HS, et al.
Journal of neuromuscular diseases 2026; 22143602261478703 doi:10.1177/22143602261478703.
PMID: 42615581 - 6
More Than Muscle Aches: A Case of Statin-Associated Necrotizing Myositis.
Chen A, Deliscar L, Ditty K, Moon A
Cureus 2026; (18(7)):e113089 doi:10.7759/cureus.113089.
PMID: 42626528 - 7
Association of anti-HMGCR antibodies of the IgM isotype with refractory immune-mediated necrotizing myopathy.
Yang H, Sun C, Ye L, et al.
Arthritis research & therapy 2024; (26(1)):158 doi:10.1186/s13075-024-03387-6.
PMID: 39261921 - 8
Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients.
Bonanno S, Salvi E, Cheli M, et al.
Journal of neurology 2026; (273(9)).
PMID: 42671644 - 9
Dysphagia as the Initial Manifestation of Anti-HMGCR Antibody-Positive Immune-Mediated Necrotizing Myopathy Complicated by Pulmonary Embolism.
Kalluri R, Ciofoaia E, Adetimehin O, et al.
Case reports in rheumatology 2026; (2026()):2235175 doi:10.1155/crrh/2235175.
PMID: 42984811
This page is for informational purposes only and does not constitute medical advice. It cannot determine whether your IMNM has relapsed; contact your care team about new symptoms or lab changes, and seek emergency help for inability to swallow, choking, or shortness of breath.